Vives Louvain Technology Fund logo

Vives Louvain Technology Fund

Europe, Vlaams-Brabant, Belgium, Louvain-la-neuve

Description

Vives Louvain Technology Fund is a multi-sector technology fund based in Louvain-la-Neuve, Belgium, with a strong strategic partnership with UCLouvain. The fund's primary mission is to valorize research and foster the growth of innovative deep tech companies, often originating as spin-offs from UCLouvain and other Belgian universities, alongside other promising early-stage ventures. Vives plays a crucial role in bridging academic research with commercial application, providing essential capital and strategic support to nascent technologies.

The fund has successfully raised significant capital across multiple iterations, demonstrating its enduring commitment to the Belgian tech ecosystem. Collectively, Vives I (launched in 2010), Vives II (2016), and Vives III (2022) have amassed over €100 million in capital. The most recent fund, Vives III, specifically commands a capital of €40 million, underscoring its capacity for new investments and continued support for its portfolio.

Vives focuses on seed and early-stage investments, targeting companies across a diverse range of technology sectors including biotech, medtech, deeptech, engineering, IT, and cleantech. Their typical initial investment in a first round ranges from €200,000 to €2 million, with a clear strategy for providing follow-on funding to support portfolio companies through subsequent growth stages. To date, Vives has invested in more than 30 companies, actively contributing to the development and scaling of high-potential ventures within Belgium and beyond. The fund prides itself on offering not just capital, but also active guidance, leveraging its extensive network and expertise to help entrepreneurs navigate the challenges of commercialization and market expansion.

Investor Profile

Vives Louvain Technology Fund has backed more than 25 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 4% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series Unknown rounds (top funding stages).
  • Majority of deals are located in Belgium, France, United States.
  • Strong thematic focus on Health Care, Biotechnology, Wellness.
  • Typical check size: $200K – $2M.

Stage Focus

  • Series B (36%)
  • Series A (36%)
  • Series Unknown (12%)
  • Seed (12%)
  • Series C (4%)

Country Focus

  • Belgium (76%)
  • France (12%)
  • United States (8%)

Industry Focus

  • Health Care
  • Biotechnology
  • Wellness
  • Agtech
  • Dietary Supplements
  • Nutraceutical
  • Electronics
  • Medical
  • Therapeutics
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Vives Louvain Technology Fund frequently co-invest with?

New Science Ventures
North America, Connecticut, United States, Greenwich
Co-Investments: 3
Gemma Frisius Fund
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 3
AI
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 3
VIB
Europe, Oost-Vlaanderen, Belgium, Gent
Co-Investments: 4
Fund+
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 4
V-Bio Ventures
Europe, Oost-Vlaanderen, Belgium, Gent
Co-Investments: 5
N
Europe, Vlaams-Brabant, Belgium, Louvain-la-neuve
Co-Investments: 3
European Innovation Council
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 3
S.R.I.W.
Europe, Liege, Belgium, Liège
Co-Investments: 9
PMV
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 3

Which angels does Vives Louvain Technology Fund often collaborate with?

OV
Europe, Belgium
Shared Deals: 1
PD
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Shared Deals: 1

What are some of recent deals done by Vives Louvain Technology Fund?

Sunrise

Brussels, Brussels Hoofdstedelijk Gewest, Belgium

We are a virtual sleep clinic, using our own 3-gram sensor to diagnose sleep with gold standard quality.

Health CareHealth DiagnosticsHome Health CareLifestyleMedical DeviceWellness
Series AMar 9, 2023
Amount Raised: $17,996,293
Novadip Biosciences

Mont-saint-guibert, Brabant Wallon, Belgium

Novadip is transforming the lives of patients using its unique “3M3” tissue regeneration technology platform.

BiotechnologyHealth CareMedicalTherapeutics
Series BNov 3, 2022
Amount Raised: $23,398,518
BOTALYS

Ghislenghien, Hainaut, Belgium

We seek wild precision for the Nutraceutical industry by developing pristine bioactive botanicals, using indoor farming.

AgTechBiotechnologyDietary SupplementsHealth CareNutraceuticalWellness
Series BOct 4, 2022
Amount Raised: $6,639,040

Spinovit is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction.

Health CareHealth DiagnosticsMedical Device
SeedJan 1, 2022
Sunrise

Brussels, Brussels Hoofdstedelijk Gewest, Belgium

We are a virtual sleep clinic, using our own 3-gram sensor to diagnose sleep with gold standard quality.

Health CareHealth DiagnosticsHome Health CareLifestyleMedical DeviceWellness
SeedDec 15, 2021
Amount Raised: $7,338,604
Novadip Biosciences

Mont-saint-guibert, Brabant Wallon, Belgium

Novadip is transforming the lives of patients using its unique “3M3” tissue regeneration technology platform.

BiotechnologyHealth CareMedicalTherapeutics
Series BOct 28, 2021
Amount Raised: $22,196,495
Aphea.Bio

Zwijnaarde, Oost-Vlaanderen, Belgium

Aphea.Bio offers research and development in the areas of bioinsecticides and bioherbicides.

AgricultureBiotechnologyChemical
Series BApr 14, 2021
Amount Raised: $21,572,387
Aphea.Bio

Zwijnaarde, Oost-Vlaanderen, Belgium

Aphea.Bio offers research and development in the areas of bioinsecticides and bioherbicides.

AgricultureBiotechnologyChemical
Series BApr 1, 2021
Amount Raised: $4,711,425
Syndesi Therapeutics

Louvain-la-neuve, Vlaams-Brabant, Belgium

Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.

BiotechnologyHealth CarePharmaceutical
Series ASep 28, 2020
Amount Raised: $7,007,103
ExeVir Bio

Zwijnaarde, Oost-Vlaanderen, Belgium

ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections.

BiotechnologyHealth CareLife ScienceTherapeutics
Series AJul 28, 2020
Amount Raised: $49,218,885